Home > Riviste > Minerva Respiratory Medicine > Fascicoli precedenti > Minerva Respiratory Medicine 2021 December;60(4) > Minerva Respiratory Medicine 2021 December;60(4):136-41

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

REVIEW   

Minerva Respiratory Medicine 2021 December;60(4):136-41

DOI: 10.23736/S2784-8477.21.01921-0

Copyright © 2021 EDIZIONI MINERVA MEDICA

lingua: Inglese

COVID-19 vaccines: challenges and solutions

Zeinab MOHSENI AFSHAR 1, Arefeh BABAZADEH 2, Alireza JANBAKHSH 1, Mandana AFSHARIAN 1, Soheil EBRAHIMPOUR 2

1 Clinical Research Development Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran; 2 Infectious Diseases and Tropical Medicine Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran



Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was declared a global emergency by the World Health Organization (WHO). Several ways have been used to control and manage the COVID-19 pandemic. Among them, development of vaccines could be an important breakthrough against novel virus. It is important to note that the candidate vaccine is expected to work against infection and transmission. To date, many COVID-19 vaccine clinical trials have been registered worldwide. However, some vaccine candidates could meet adequate standards for effectiveness and safety. In the current review, we discussed the effectiveness, safety, target population, and hesitancy of COVID-19 vaccines.


KEY WORDS: SARS-CoV-2; COVID-19; Vaccines

inizio pagina